Principal Securities Inc. Sells 8,920 Shares of Sanofi (NASDAQ:SNY)

Principal Securities Inc. lowered its position in Sanofi (NASDAQ:SNY) by 19.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 36,130 shares of the company’s stock after selling 8,920 shares during the period. Principal Securities Inc.’s holdings in Sanofi were worth $1,743,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Synergy Asset Management LLC bought a new position in Sanofi in the fourth quarter worth $25,000. McClarren Financial Advisors Inc. increased its stake in shares of Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares in the last quarter. Northwest Investment Counselors LLC purchased a new position in Sanofi during the 3rd quarter valued at about $29,000. Concord Wealth Partners boosted its stake in Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares in the last quarter. Finally, Fortitude Family Office LLC grew its holdings in Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after purchasing an additional 659 shares during the period. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Price Performance

NASDAQ SNY opened at $53.95 on Wednesday. Sanofi has a one year low of $45.22 and a one year high of $58.97. The stock has a 50-day moving average of $50.54 and a 200 day moving average of $52.48. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.74 and a current ratio of 1.46. The company has a market capitalization of $136.92 billion, a price-to-earnings ratio of 21.67, a PEG ratio of 0.99 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. On average, sell-side analysts forecast that Sanofi will post 4.36 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on SNY. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.